OBJECTIVE: To determine if a single intravitreal injection of 4 mg of @entity2995 in @entity1 with classic @entity1940 associated with age-related @entity1020 can safely reduce the risk of severe @entity227 . METHODS: A double-masked, placebo-controlled, randomized clinical trial was performed in @entity1 60 years or older who had @entity1940 with any classic component, a duration of symptoms of less than 1 year, and a visual acuity of 20/200 or better. Best-corrected visual acuity, intraocular pressure, and @entity231 grading were performed before the injection and then at 3, 6, and 12 months. MAIN OUTCOME MEASURE: The development of severe @entity1018 (30 letters) by survival analysis on an intention-to-treat basis. RESULTS: One hundred fifty-one eyes were randomized into the study, and follow-up data were obtained for 73 (97%) of the 75 eyes in the treated group and for 70 (92%) of the 76 eyes in the control group. There was no difference between the 2 groups for the development of severe @entity227 during the first year of the study (log-rank chi 2(1) = 0.03, P =.90). In both groups, the 12-month risk of severe @entity227 was 35%, with a hazard ratio of 1.05 (95% confidence interval, 0.59-1.86). The change in size of the neovascular membranes, however, was significantly less in eyes receiving @entity2713 than in those receiving placebo 3 months after treatment (P =.01), although no difference was noted after 12 months. After 12 months, treated eyes had a significantly higher risk of an elevated intraocular pressure (31/75 [41%] vs 3/76 [4%]; P<.001), but not of @entity231 progression (P =.29). CONCLUSIONS: A single dose of intravitreal @entity2713 had no effect on the risk of loss of visual acuity during the first year of the study in eyes with age-related @entity1020 and classic @entity1940 , despite a significant antiangiogenic effect found 3 months after treatment. This biological effect warrants further study.

A randomized clinical trial of a single dose of intravitreal @entity2995 for neovascular age-related XXXX : one-year results.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1018 :: ('MESH:D054062', 'Disease') :: ['loss of vision'] @entity2995 :: ('MESH:D014222', 'Chemical') :: ['triamcinolone acetonide'] @entity227 :: ('MESH:D014786', 'Disease') :: ['visual loss'] @entity1940 :: ('MESH:D020256', 'Disease') :: ['choroidal neovascularization'] @entity231 :: ('MESH:D002386', 'Disease') :: ['cataract'] @entity1020 :: ('MESH:D008268', 'Disease') :: ['macular degeneration'] @entity2713 :: ('MESH:D014221', 'Chemical') :: ['triamcinolone']
@entity1020 :: (MESH:D008268,Disease) :: ['macular degeneration']
